GBA Presents: THE BARE ESSENTIALS

Ginkgo Bioworks rises 22.2% 12:00 DNA Ginkgo Biowork


Lovesac skyrockets after earnings smasher + 22% :wtf:
Mar. 29, 2022 10:41 AM ETThe Lovesac Company (LOVE)


The Lovesac Company (NASDAQ:LOVE) soared on Tuesday after the retailer cruised past estimates with its Q4 earnings report.

Sales were up 51% for the quarter due largely to higher sales volume and lower promotional discounting. Showroom sales, which include kiosks and mobile concierges, wereup 59.8% for the period, while Internet sales rose 22.8% and an increase of 164.9% was recorded in the Other channel category.

Gross profit was up 46% during the quarter. An increase in total freight including tariffs and warehousing costs over the prior year period was said to be principally related to a 590 basis point increase in inbound container freight costs and increased tariffs related to higher product sourcing from China, partially offset by a 110 basis point improvement due to higher leverage of warehousing and outbound freight costs.

Operating expenses rose 60% during the quarter to help take down the gross margin rate from 57.9% to 55.9%.

Adjusted EBITDA rose 23.6% for Lovesac (LOVE) to $32.0M.
 
Evercore bumps oil price forecast, UBS lifts European energy price targets


  • Tuesday, Evercore analyst Stephen Richardson lifted the bank's oil price forecast to $104/b for 2022
 
DoubleVerify is the only fully accredited programmatic suite in the market today.


Accreditations DoubleVerify (Investor Presentation)

As a result of its accredited and differentiated offerings, customers currently impressively include over 50 of the top 100 global advertisers including Colgate-Palmolive (CL), Ford (F), Mondelēz (MDLZ), and Pfizer (PFE).

They said on TV Cyber Security stks were down and yet DV is up a Buck what makes it slightly different?
 
Investing is funny... despite all these damn winners --the one that got away always irritates.
I cannot get WOLF out of my mind...

I had everything going the research the chart point the Market... what stopped me!<----

This innate hatred of tech perhaps.. I gave the idea to Van and he said soemthing like Oh I'll look into it.. will it be better than the average Semi....

man... King Alpha here... way better than any semi.... so mad...
 
stonedinvestor said:
  • Director of Evolv Technologies (EVLV) Kevin Charlton purchased 100,000 shares of company stock at $1.82 per share for a total transaction amount of $182,420
  • Director of Revolution Medicines (RVMD) Thilo Schroeder purchased 232,364 shares of company stock at $23.63 per share for a total transaction amount of $5,489,623

  • Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022
    a80dee2d4a8acb423d8095dbdf6a84d4

    Revolution Medicines, Inc.

    Pipeline of Development-Stage RAS(ON) Inhibitors to be Highlighted in Four Presentations in “Targeting the RAS Oncogene” Session, as well as Presentations in “Chemistry to the Clinic” and “Challenging Targets” Sessions and Pediatric Cancer Working Group Town Hall Meeting

    REDWOOD CITY, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company will make seven oral presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 being held April 8-13, 2022 in New Orleans, Louisiana.

  • Revolution Medicines(RVMD)

    The first stock we’ll look at, Revolution Medicines, is a precision oncology company working on two innovative research tracks designed to specifically inhibit frontier targets in RAS-addicted cancers. Revolution’s pipeline includes three drug candidates on the RAS companion inhibitor track, including two that have reached the stage of human clinical trials, and five more drug candidates in the RAS(ON) inhibitor track. All of the latter are in preclinical stages, with four of them in the process of preparing and submitting Investigational New Drug (IND) applications.

    On the RAS(ON) track, four of Revolution’s drug candidates are approaching the end of preclinical studies. RMC-6236, -6291, -9805, and -8839 are tri-complex inhibitors which Revolution Medicines has developed through its proprietary RAS(ON) platform. These drugs target ‘diverse oncogenic RAS variants,’ using a wide range of differentiated chemical and pharmacological profiles. The first two on track for IND completion in 1H22, while the second two are expected to complete their IND submissions in 2023.

    Turning to the clinical trials, we find that RMC-4630 is Revolution’s most advanced drug candidate so far. This drug is an SHP2 inhibitor, and is the subject of a global Phase 2 study, in combination with sotorasib, as a potential treatment for advanced non-small cell lung cancer. The company expects to complete enrollment in this study during 2H22, and to begin releasing data on clinical benefits before the end of the year. Additional data is expected during 2023. Revolution is conducting this study in partnership with Sanofi, and in 4Q21 the company received $9.5 million from Sanofi per the terms of their collaboration agreement.

    Revolution has one other clinical trial in progress, a Phase 1/1b study of RMC-5552. This drug, described as a ‘potent, selective bi-steric inhibitor of mTORC1,’ is in the dose escalation stage of the study, and the company recently released preliminary data showing positive clinical activity. The company plans on releasing additional data from this study of RMC-5552 as a single agent during 2023.

    Looking at the insider trades, we find that one Board member, Director Thilo Schroeder, has been making numerous large-sum purchases of RVMD stock. His most recent purchase, made on March 24 for $5.489 million, totaled 232,364 shares. His largest purchase, from March 4, was for 1.088 million shares and cost him $28.62 million. Overall, Schroeder has spent over $43 million on Revolution’s stock this month.

    Schroeder is not the only bull on this clinical-stage biopharma. Leerink analyst Jonathan Chang also takes a strongly positive stance here, writing: “We continue to have a positive long-term view on the stock based on RVMD's experienced management team, promising preclinical data for the innovative RAS(ON) platform, and large addressable population of RAS-dependent cancers. While the RAS pathway drug development landscape is highly competitive, we believe RVMD has a differentiated approach and the scientific ability to solve these challenging targets.”

    These upbeat comments back up Chang’s Outperform (i.e. Buy) rating on RVMD, and his $31 price target suggests the stock has a one-year upside of ~26%.
More...



RVMD $5 mil insider by is nothing to sneeze at especially before important presentations....
 
You must log in or register to reply here.
Back
Top